Prospects of Curcumin Nanoformulations in Cancer Management.
Hilda AmekyehEnas AlkhaderRayan SabraNashiru BillaPublished in: Molecules (Basel, Switzerland) (2022)
There is increasing interest in the use of natural compounds with beneficial pharmacological effects for managing diseases. Curcumin (CUR) is a phytochemical that is reportedly effective against some cancers through its ability to regulate signaling pathways and protein expression in cancer development and progression. Unfortunately, its use is limited due to its hydrophobicity, low bioavailability, chemical instability, photodegradation, and fast metabolism. Nanoparticles (NPs) are drug delivery systems that can increase the bioavailability of hydrophobic drugs and improve drug targeting to cancer cells via different mechanisms and formulation techniques. In this review, we have discussed various CUR-NPs that have been evaluated for their potential use in treating cancers. Formulations reviewed include lipid, gold, zinc oxide, magnetic, polymeric, and silica NPs, as well as micelles, dendrimers, nanogels, cyclodextrin complexes, and liposomes, with an emphasis on their formulation and characteristics. CUR incorporation into the NPs enhanced its pharmaceutical and therapeutic significance with respect to solubility, absorption, bioavailability, stability, plasma half-life, targeted delivery, and anticancer effect. Our review shows that several CUR-NPs have promising anticancer activity; however, clinical reports on them are limited. We believe that clinical trials must be conducted on CUR-NPs to ensure their effective translation into clinical applications.
Keyphrases
- oxide nanoparticles
- drug delivery
- papillary thyroid
- clinical trial
- cancer therapy
- drug release
- squamous cell
- signaling pathway
- childhood cancer
- squamous cell carcinoma
- pi k akt
- molecularly imprinted
- epithelial mesenchymal transition
- young adults
- risk assessment
- adverse drug
- emergency department
- mass spectrometry
- drug induced
- high resolution
- cell proliferation
- current status
- phase iii
- double blind